Pangea Bio develops novel therapeutics for central nervous system disorders by leveraging AI and natural biological systems. Their lead program targets the TrkB receptor pathway to promote neuroplasticity and neuronal survival, aiming to create transformative treatments for neurological and mental health conditions.
Funding
Funding not disclosed
Founders
Product
Problem
Neurological and mental health disorders represent a significant and growing global health challenge, characterized by complex disease mechanisms and a high unmet medical need. Current therapeutic approaches often fall short, with a substantial percentage of patients experiencing limited efficacy or treatment resistance. This necessitates the development of novel therapeutic modalities that can effectively target underlying disease pathways to promote neuronal health and function.
Solution
Pangea Bio is a drug discovery company focused on developing novel therapeutics for central nervous system (CNS) disorders. The company's core strategy leverages AI and insights from natural biological systems to build a scalable pipeline of drug candidates. Their lead R&D program targets the TrkB receptor pathway, a critical signaling cascade involved in promoting neuroplasticity and neuronal survival. By activating this pathway, Pangea Bio aims to address multiple disease hallmarks, including neuroinflammation and pathological protein aggregation, to create transformative treatments for patients with significant unmet needs in neurological and mental health conditions.
Target Audience
Pangea Bio targets pharmaceutical companies and research institutions focused on CNS drug development, as well as patients and healthcare providers seeking advanced treatments for neurological and mental health disorders.
Features
- Proprietary small molecule compound, OT-003, designed to activate the TrkB receptor.
- Development of a pipeline of next-generation TrkB activators with varied pharmacokinetic profiles for distinct neurological disorders.
- AI-driven platform for identifying and developing naturally inspired drug candidates.
- Focus on targeting pathways implicated in neuroplasticity, neuronal survival, and neuroinflammation.
- Lead asset OT-003 demonstrates compelling efficacy in cellular and in vivo CNS disease models.
- Planned regulatory submission for Phase 1 studies of OT-003 in 2025.
- Research into activating TrkB signaling to reduce neuroinflammation and pathological protein aggregates such as α-synuclein, amyloid-β, and tau.
- Exploration of TrkB activation's role in improving mitochondrial function and endogenous BDNF production.